Public Employees Retirement Association of Colorado Takes Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Public Employees Retirement Association of Colorado purchased a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBHFree Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 30,619 shares of the medical equipment provider’s stock, valued at approximately $3,726,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Naples Money Management LLC purchased a new position in shares of Zimmer Biomet during the fourth quarter worth about $35,000. Activest Wealth Management grew its holdings in shares of Zimmer Biomet by 410.4% during the fourth quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 275 shares in the last quarter. Blue Trust Inc. grew its holdings in shares of Zimmer Biomet by 48.4% during the fourth quarter. Blue Trust Inc. now owns 469 shares of the medical equipment provider’s stock worth $52,000 after purchasing an additional 153 shares in the last quarter. Quent Capital LLC grew its holdings in shares of Zimmer Biomet by 21.6% during the fourth quarter. Quent Capital LLC now owns 518 shares of the medical equipment provider’s stock worth $63,000 after purchasing an additional 92 shares in the last quarter. Finally, GAMMA Investing LLC purchased a new position in shares of Zimmer Biomet during the fourth quarter worth about $65,000. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $113.34 on Friday. The stock has a fifty day moving average of $120.60 and a 200 day moving average of $122.01. Zimmer Biomet Holdings, Inc. has a 52 week low of $102.00 and a 52 week high of $147.50. The firm has a market capitalization of $23.32 billion, a price-to-earnings ratio of 24.53, a PEG ratio of 2.04 and a beta of 1.02. The company has a quick ratio of 0.80, a current ratio of 1.66 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBHGet Free Report) last announced its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 EPS for the quarter, topping analysts’ consensus estimates of $1.87 by $0.07. Zimmer Biomet had a return on equity of 12.70% and a net margin of 12.93%. The company had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.87 billion. During the same quarter last year, the firm posted $1.89 earnings per share. The firm’s revenue was up 3.2% on a year-over-year basis. As a group, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.1 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 31st. Shareholders of record on Wednesday, June 26th will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.85%. The ex-dividend date is Wednesday, June 26th. Zimmer Biomet’s dividend payout ratio is currently 20.78%.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Evercore ISI boosted their price objective on Zimmer Biomet from $125.00 to $130.00 and gave the stock an “in-line” rating in a report on Thursday, April 4th. Barclays cut their target price on Zimmer Biomet from $130.00 to $125.00 and set an “underweight” rating for the company in a research note on Friday, May 31st. StockNews.com lowered Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a research note on Monday, February 19th. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research note on Thursday, May 30th. Finally, Canaccord Genuity Group reaffirmed a “hold” rating and issued a $130.00 target price on shares of Zimmer Biomet in a research note on Friday, February 23rd. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $133.75.

Read Our Latest Report on Zimmer Biomet

About Zimmer Biomet

(Free Report)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

See Also

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBHFree Report).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.